Histologic Inflammation With IBD Tied to Serious Infections
By Lori Solomon HealthDay Reporter
FRIDAY, Dec. 8, 2023 -- Histologic inflammation with inflammatory bowel disease (IBD) is an independent risk factor for serious infections, according to a study published online Oct. 29 in Clinical Gastroenterology and Hepatology.
Karl Mårild, M.D., Ph.D., from Sahlgrenska Academy in Gothenburg, Sweden, and colleagues assessed whether serious infection risk varies by IBD histologic disease activity. The analysis included 55,626 individuals diagnosed with IBD (1990 to 2016).
The researchers found that risk for serious infection was higher for histologic inflammation versus remission (4.62 and 2.53 serious infections per 100 person-years of follow-up, respectively; adjusted hazard ratio [aHR], 1.59). There was also an increased risk for serious infection for histologic inflammation in both ulcerative colitis (aHR, 1.68) and Crohn disease (aHR, 1.59) compared with remission. A higher risk for sepsis and opportunistic infections were also seen (aHRs, 1.66 and 1.71, respectively). Results were consistent across age groups, sex, and education level and persisted after adjusting for IBD-related medications (aHR, 1.47).
"Compared with IBD patients in remission, IBD patients with histologic inflammation had an increased risk of serious infections overall and across infectious disease categories, including sepsis," the authors write. "Our findings suggest that achieving histologic remission of IBD may reduce the risk of serious infections."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted December 2023
Read this next
Risankizumab Noninferior, Superior to Ustekinumab for Crohn Disease
WEDNESDAY, July 17, 2024 -- For patients with moderate-to-severe Crohn disease, risankizumab is noninferior to ustekinumab for clinical remission at week 24 and is superior for...
No Link Seen Between Exposure to Immunosuppressive Therapy, Cancer in IBD Patients
TUESDAY, June 11, 2024 -- There is no significant association between exposure to immunosuppressive therapies and development of incident cancers among patients with inflammatory...
Inappropriate Antibiotic Prescribing Identified in Safety-Net Populations
THURSDAY, May 30, 2024 -- Inappropriate antibiotic prescribing is common with or without a plausible antibiotic indication, and inappropriate prescribing is also common in U.S...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.